SCHEMBL2646437

SCHEMBL2646437

O=C(O)/C(=C/C1CCCC1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.47
TAS1R3 Q7RTX0 1/20 0.45
TAS1R2 Q8TE23 1/20 0.45
KMO O15229 2/20 0.44
HPGD P15428 1/20 0.43
SRD5A2 P31213 1/20 0.42
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
AGTR1 P30556 1/20 0.41
SIGMAR1 Q99720 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
KDM2B Q8NHM5 1/20 0.40
HCRTR1 O43613 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2646441 1.00 TSHR (0.47) TSHRTAS1R3TAS1R2KMOHPGD
SCHEMBL2647437 0.83 TAS1R3 (0.47) TSHRTAS1R3TAS1R2HPGDKMT2A
SCHEMBL2647434 0.83 TAS1R3 (0.47) TSHRTAS1R3TAS1R2HPGDKMT2A
SCHEMBL1171734 0.83 GCK (0.52) TAS1R3TAS1R2SIGMAR1
SCHEMBL1171737 0.83 GCK (0.52) TAS1R3TAS1R2SIGMAR1
SCHEMBL1171340 0.82 GCK (0.51) TAS1R3TAS1R2
SCHEMBL1171343 0.82 GCK (0.51) TAS1R3TAS1R2
SCHEMBL2648502 0.81 GCK (0.39) TSHRTAS1R3TAS1R2KMT2AALDH1A1
SCHEMBL2648496 0.81 GCK (0.39) TSHRTAS1R3TAS1R2KMT2AALDH1A1
SCHEMBL2650025 0.80 GCK (0.33) TAS1R3TAS1R2ALDH1A1LMNAAGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1242397-B1 TRANS OLEFINIC GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2005-09-28 EP disclosed
EP-1242397-A1 TRANS OLEFINIC GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2002-09-25 EP disclosed
US-6353111-B1 WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES; 2,3-DI-SUBSTITUTED TRANS OLEFINIC N-HETEROAROMATIC OR URIDO PROPIONAMIDES: THE SUBSTITUTION AT THE 2-POSITION BEING A SUBSTITUTED PHENYL GROUP AND AT THE 3-POSITION A HOFFMANN-LA ROCHE INC. 2002-03-05 US disclosed
WO-2001044216-A1 TRANS OLEFINIC GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2001-06-21 WO disclosed